Your browser doesn't support javascript.
Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
Kalkowska, Dominika A; Pallansch, Mark A; Wilkinson, Amanda; Bandyopadhyay, Ananda S; Konopka-Anstadt, Jennifer L; Burns, Cara C; Oberste, M Steven; Wassilak, Steven G F; Badizadegan, Kamran; Thompson, Kimberly M.
  • Kalkowska DA; Kid Risk, Inc., Orlando, FL, USA.
  • Pallansch MA; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Wilkinson A; Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Bandyopadhyay AS; Bill and Melinda Gates Foundation, Seattle, WA, USA.
  • Konopka-Anstadt JL; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Burns CC; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Oberste MS; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Wassilak SGF; Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Badizadegan K; Kid Risk, Inc., Orlando, FL, USA.
  • Thompson KM; Kid Risk, Inc., Orlando, FL, USA.
Risk Anal ; 41(2): 329-348, 2021 02.
Article in English | MEDLINE | ID: covidwho-916943
ABSTRACT
Delays in achieving the global eradication of wild poliovirus transmission continue to postpone subsequent cessation of all oral poliovirus vaccine (OPV) use. Countries must stop OPV use to end all cases of poliomyelitis, including vaccine-associated paralytic polio (VAPP) and cases caused by vaccine-derived polioviruses (VDPVs). The Global Polio Eradication Initiative (GPEI) coordinated global cessation of all type 2 OPV (OPV2) use in routine immunization in 2016 but did not successfully end the transmission of type 2 VDPVs (VDPV2s), and consequently continues to use type 2 OPV (OPV2) for outbreak response activities. Using an updated global poliovirus transmission and OPV evolution model, we characterize outbreak response options for 2019-2029 related to responding to VDPV2 outbreaks with a genetically stabilized novel OPV (nOPV2) strain or with the currently licensed monovalent OPV2 (mOPV2). Given uncertainties about the properties of nOPV2, we model different assumptions that appear consistent with the evidence on nOPV2 to date. Using nOPV2 to respond to detected cases may reduce the expected VDPV and VAPP cases and the risk of needing to restart OPV2 use in routine immunization compared to mOPV2 use for outbreak response. The actual properties, availability, and use of nOPV2 will determine its effects on type 2 poliovirus transmission in populations. Even with optimal nOPV2 performance, countries and the GPEI would still likely need to restart OPV2 use in routine immunization in OPV-using countries if operational improvements in outbreak response to stop the transmission of cVDPV2s are not implemented effectively.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Poliomyelitis / Poliovirus Vaccine, Oral / Disease Outbreaks / Risk Assessment / Poliovirus / Disease Eradication Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Risk Anal Year: 2021 Document Type: Article Affiliation country: Risa.13622

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Poliomyelitis / Poliovirus Vaccine, Oral / Disease Outbreaks / Risk Assessment / Poliovirus / Disease Eradication Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Risk Anal Year: 2021 Document Type: Article Affiliation country: Risa.13622